2-oxindole-3-acetic acid: personal communication from searcher Ellen V. Todd Alabama Center 1/72 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
2-oxindole-3-acetic acid : A member of the class of oxindoles that is 2-oxindole carrying a carboxymethyl substituent at position 3. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 3080590 |
| CHEMBL ID | 443641 |
| CHEBI ID | 133221 |
| SCHEMBL ID | 1302976 |
| MeSH ID | M0043921 |
| Synonym |
|---|
| 1h-indole-3-acetic acid, 2,3-dihydro-2-oxo- |
| 2-oxindole-3-acetic acid |
| (2-oxo-2,3-dihydro-1h-indol-3-yl)acetic acid |
| 2971-31-5 |
| oxindole-3-acetic acid |
| CHEBI:133221 |
| 2-oxindol-3-yl-acetic acid |
| AKOS000506116 |
| CHEMBL443641 |
| 2-(2-oxo-1,3-dihydroindol-3-yl)acetic acid |
| 2-(2-oxo-2,3-dihydro-1h-indol-3-yl)acetic acid |
| EN300-59490 |
| SCHEMBL1302976 |
| STK523902 |
| FT-0683524 |
| 2-(2-oxoindolin-3-yl)acetic acid |
| AM20040124 |
| AKOS016345720 |
| (2-oxo-2,3-dihydro-1h-indol-3-yl)-acetic acid |
| AB49450 |
| 2-hydroxy-1h-indole-3-acetic acid |
| 1h-indole-3-aceticacid,2,3-dihydro-2-oxo- |
| (2-oxo-2,3-dihydro-1h-indol-3-yl)acetic acid, aldrichcpr |
| mfcd09035909 |
| 2-(2-oxo-3-indolinyl)acetic acid |
| xi-2,3-dihydro-2-oxo-1h-indole-3-acetic acid |
| J-017610 |
| 2-(2-oxoindolin-3-yl)aceticacid |
| F10191 |
| 2-(2-oxo-1,3-dihydroindol-3-yl)acetate |
| C22202 |
| DTXSID30952164 |
| (2-hydroxy-3h-indol-3-yl)acetato |
| 2-oxindole-3-aceticacid |
| LS-03835 |
| CS-0131902 |
| Z336080924 |
| Role | Description |
|---|---|
| plant metabolite | Any eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| monocarboxylic acid | An oxoacid containing a single carboxy group. |
| indole-3-acetic acids | An indol-3-yl carboxylic acid in which the carboxylic acid specified is acetic acid. |
| oxindoles | Any member of the class of indolones whose structure is based on an oxindole (2-indolone) skeleton. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID402872 | In vivo antitumor activity against mouse S180 cells implanted in mouse after 10 days | 1997 | Journal of natural products, Apr, Volume: 60, Issue:4 | The secalosides, novel tumor cell growth inhibitory glycosides from a pollen extract. |
| AID402868 | In vivo antitumor activity against mouse S180 cells implanted in mouse assessed as cell growth at 5 ug/mouse for 10 days relative to control | 1997 | Journal of natural products, Apr, Volume: 60, Issue:4 | The secalosides, novel tumor cell growth inhibitory glycosides from a pollen extract. |
| AID402867 | In vivo antitumor activity against mouse S180 cells implanted in mouse assessed as cell growth at 10 ug/mouse for 10 days relative to control | 1997 | Journal of natural products, Apr, Volume: 60, Issue:4 | The secalosides, novel tumor cell growth inhibitory glycosides from a pollen extract. |
| AID402870 | In vivo antitumor activity against mouse S180 cells implanted in mouse assessed as cell growth at 1.25 ug/mouse for 10 days relative to control | 1997 | Journal of natural products, Apr, Volume: 60, Issue:4 | The secalosides, novel tumor cell growth inhibitory glycosides from a pollen extract. |
| AID402869 | In vivo antitumor activity against mouse S180 cells implanted in mouse assessed as cell growth at 2.5 ug/mouse for 10 days relative to control | 1997 | Journal of natural products, Apr, Volume: 60, Issue:4 | The secalosides, novel tumor cell growth inhibitory glycosides from a pollen extract. |
| AID402866 | In vivo antitumor activity against mouse S180 cells implanted in mouse assessed as cell growth at 20 ug/mouse for 10 days relative to control | 1997 | Journal of natural products, Apr, Volume: 60, Issue:4 | The secalosides, novel tumor cell growth inhibitory glycosides from a pollen extract. |
| AID402871 | In vivo antitumor activity against mouse S180 cells implanted in mouse assessed as cell growth at 0.625 ug/mouse for 10 days relative to control | 1997 | Journal of natural products, Apr, Volume: 60, Issue:4 | The secalosides, novel tumor cell growth inhibitory glycosides from a pollen extract. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 4 (40.00) | 18.7374 |
| 1990's | 1 (10.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (40.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.51) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 10 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||